Islet Sciences, Inc. Announces Peer-Reviewed Publication of Study Validating Novel Diabetes Diagnostic
July 16, 2014 08:10 ET
|
Islet Sciences, Inc.
RALEIGH, N.C., July 16, 2014 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic...
Islet Sciences, Inc. Appoints William Wilkison, Ph.D. to Board of Directors
April 21, 2014 09:34 ET
|
Islet Sciences, Inc.
RALEIGH, N.C., April 21, 2014 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT) today announced the appointment of Dr. William Wilkison, COO of Islet Sciences, to Islet's Board of...
Islet Sciences Announces Positive 12-Week Phase 2 Clinical Results for SGLT2 Inhibitor Remogliflozin Etabonate
April 16, 2014 12:16 ET
|
Islet Sciences, Inc.
RALEIGH, N.C., April 16, 2014 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT) and BHV Pharma today announced positive results from two 12-week phase 2b clinical studies of remogliflozin...
Islet Sciences Signs Cell Therapy Alliance and Service Agreement With Progenitor Cell Therapy
January 12, 2012 08:00 ET
|
Islet Sciences, Inc.
NEW YORK, Jan. 12, 2012 (GLOBE NEWSWIRE) -- Islet Sciences, Inc., a wholly-owned subsidiary of One E-Commerce Corporation (OTCBB:ONCE) a biotechnology company engaged in the research, development and...